172 Patients Complete Treatment: Biofrontera's Breakthrough AK Therapy Could Help 58M US Adults

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic Keratoses (AK) on the Extremities, Neck and Trunk

Biofrontera Completes Enrollment and Active Treatment Phase in Phase 3 Ameluz PDT Trial for AK on the Body

Biofrontera advances closer to expanding the Ameluz PDT label, as phase 3 follow-up data on actinic keratoses are expected next year.

172 Patients Complete Treatment: Biofrontera's Breakthrough AK Therapy Could Help 58M US Adults

Biofrontera's Phase 3 trial evaluating Ameluz PDT for actinic keratoses on extremities, neck and trunk completes treatment phase. Study targets 58M US adults with AK lesions. sNDA planned for Q2 2026.